Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Robert J. Motzer, MD
Advertisement
Articles by Robert J. Motzer, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5